摘要
目的总结分析托珠单抗治疗难治性全身型幼年特发性关节炎的治疗经验,探索经济有效治疗方法。方法回顾分析2014年至2016年6例使用托珠单抗的难治性全身型幼年特发性关节炎患儿临床资料,从托珠单抗疗程、疗效、激素减量情况、不良反应及生长等方面进行描述和分析。结果 6例患儿平均年龄6岁,男女比例为1:1,病程16至63个月;均在激素及传统抗风湿病药物治疗基础上联合使用其他免疫抑制剂或生物制剂。托珠单抗治疗时间7~26个月,中位数为9.5个月。6例患儿均在托珠单抗治疗后不同时间内达到临床缓解。3例患儿在诱导缓解后用药间隔由2周渐延长,最长至4周,未出现疾病活动。除1例患儿外,其余5例平均可在托珠单抗治疗开始后5.8个月内减停激素,激素减停后生长改善。6例患儿在托珠单抗治疗期间均未出现严重不良反应。结论托珠单抗治疗难治性全身型幼年特发性关节炎安全有效,可在短期内减停激素,改善生长;可尝试在诱导缓解后延长用药间隔。
ObjectiveTo summarize the treatment experience of refractory systemic juvenile idiopathic arthritis (JIA) by tocilizumab, and to explore the cost-effective treatment. MethodsThe clinical data of 6 pediatric patients with refractory systemic JIA treated by tocilizumab from 2014 to June 2016 were retrospectively analyzed in the aspects of course and effectiveness of tocilizumab, steroid reduction, adverse reaction, and growth. ResultsThe median age of the six patients (3 males and 3 females) was 6 years, and the course of disease were from 16 to 63 months. All patients were treated by other immunosuppressive agents or biological agents in addition to steroid and traditional anti-rheumatic drug therapy. The courses of tocilizumab treatment were from 7 to 26 months and the median time was 9.5 months. All 6 patients responded to tocilizumab and achieved the clinical remission at different time. After the induced remission, the interval of the treatment intervention was increased from 2 weeks up to 4 weeks in 3 cases, and no disease activity was observed. Except one case, another 5 cases reduced and stopped the use of hormones at 5.8 months after tocilizumab treatment. After hormones was reduced and discontinued, the growth was improved. All 6 patients had no serious adverse reactions. ConclusionsTocilizumab is safe and effective for patients with refractory JIAs. The steroid can be reduced in short time to improve growth. After remission is induced, the interval of the treatment intervention could be prolonged.
出处
《临床儿科杂志》
CSCD
北大核心
2017年第6期454-457,共4页
Journal of Clinical Pediatrics